ESMO-EANM Virtual Advanced Course on Diagnostic and Therapeutic Applications of Nuclear Medicine in Oncology

Programme

ESMO VIRTUAL ADVANCED COURSE

16-17 JULY 2021

Co-Chairs
Paola A. Erba, Italy
Stefano Fanti, Italy
Florian Lordick, Germany
ESMO-EANM VIRTUAL ADVANCED COURSE PROGRAMME

DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF NUCLEAR MEDICINE IN ONCOLOGY

16-17 July 2021

CO-CHAIRS: Paola A. Erba, Italy
Stefano Fanti, Italy
Florian Lordick, Germany

SPEAKERS: Valentina Ambrosini, Italy
Lisa Bodei, United States
Désirée De andreis, Italy
Rocio Garcia-Carbonero, Spain
Daniel Heinrich, Norway
Ken Herrmann, Germany
Martha Hoffmann, Austria

Hans Hofland, Netherlands
Michael Lassmann, Germany
Aurelius G. Omlin, Switzerland
Wim J. G. Oyen, Netherlands
Marianne E. Pavel, Germany
Christos Toumpanakis, United Kingdom

LEARNING OBJECTIVES

- To get an updated analysis of the diagnostic and therapeutic applications of nuclear medicine in oncology
- To provide a knowledge of principles of both nuclear medicine modalities and systemic oncologic therapies in end-term trainees and specialists in oncology and nuclear medicine
- To provide an educational framework for in-depth analysis of the combined diagnostic/therapeutic strategies (theranostics) in oncology and scientific interaction between oncology and nuclear medicine experts

ACCREDITATION

The programme of this event has been accredited with 9 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
All timings in the programme are to be considered CEST (Central European Summer Time)

Friday, 16 July 2021

13:00-13:10 Welcome and introduction
10’ Welcome and Learning Objectives Introduction
Paola A. Erba, IT, Stefano Fanti, IT and Florian Lordick, DE

13:10-15:25 Session 1 - Introduction to Theranostics and Systemic Therapies
Martha Hoffmann, AT and Michael Lassmann, DE (Moderator: Stefano Fanti, IT)

25’ Physics background including diagnostic and therapeutic radionuclides including videos
Michael Lassmann, DE

25’ History of theranostics including radioiodine-therapy
Désirée Deandreis, IT

25’ Landscape of systemic therapies for thyroid malignancies
Martha Hoffmann, AT

15’ Discussion

45’ Workshop on Thyroid Theranostics

30’ Clinical cases presented by speakers (2x)
Martha Hoffmann, AT and Désirée Deandreis, IT

15’ Discussion

15:25-15:40 Break

15:40-17:30 Session 2 - NETs as role model for theranostics
Chairs: Rocio Garcia-Carbonero, ES and Lisa Bodei, US (Moderator: Florian Lordick, DE)

25’ Landscape of systemic therapies for NETs
Rocio Garcia-Carbonero, ES

25’ Update PRRT
Valentina Ambrosini, IT

15’ Discussion

45’ Workshop on NET theranostics

30’ Clinical cases presented by speakers (2x)
Lisa Bodei, US and Rocio Garcia-Carbonero, ES

15’ Discussion
Saturday, 17 July 2021

09:30-11:30  Session 3 - How to run a theranostic unit and beyond
Chairs: Christos Toumpanakis, UK and Ken Herrmann, DE
(Moderator: Paola A. Erba, IT and Stefano Fanti, IT)

30' Setting up a theranostic unit (regulatory, radiation safety and reimbursement challenges) including videos
Ken Herrmann, DE and Hans Hofland, NL

15' Discussion

30' Workshop on MDT: The role of the MDT in optimal patient management

15' Clinical case presented by speakers (1x)
Christos Toumpanakis, UK
15' Discussion

30' Outlook towards new theranostic concepts (combination, alpha, antibody)
Marianne E. Pavel, DE

15' Discussion

11:30-11:45  Break

11:45-14:15  Session 4 - Expanding theranostics to prostate cancer
Chairs: Aurelius G. Omlin, CH and Wim J. G. Oyen, NL
(Moderator Florian Lordick, DE and Stefano Fanti, IT)

30' Biology and treatment landscape in advanced prostate cancer and unmet medical needs
Daniel Heinrich, NO

30' Update PSMA RLT
Wim J. G. Oyen, NL

15' Discussion

30' Workshop on prostate cancer theranostics

15' Clinical case presented by speaker 1x
Aurelius G. Omlin, CH
15' Discussion

30' How to implement theranostics into residency programmes
Désirée Deandreis, IT

15' Discussion

14:15-14:30  Conclusion & Farewell
Paola A. Erba, IT, Stefano Fanti, IT and Florian Lordick, DE